Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.37 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220184 | 0.73 | EGLN1 (0.40) | EGLN1FTOEGLN2KDM4C | |
| SCHEMBL8872434 | 0.69 | EGLN1 (0.47) | EGLN1FTOEGLN2KDM4C | |
| SCHEMBL12777777 | 0.66 | EGLN1 (0.48) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL4056990 | 0.66 | EGLN1 (0.47) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL3370164 | 0.63 | EGLN1 (0.47) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL2958240 | 0.62 | EGLN1 (0.49) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL3520304 | 0.62 | EGLN3 (0.61) | EGLN1FTOEGLN2EGLN3 | |
| SCHEMBL2403988 | 0.62 | TBXAS1 (0.44) | EGLN1 | |
| SCHEMBL3848693 | 0.62 | ATM (0.44) | EGLN1FTOEGLN3BBOX1KDM4C | |
| SCHEMBL822253 | 0.61 | FTO (0.50) | EGLN1FTOEGLN2EGLN3BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | claimed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | claimed |
| CN-104427980-A | Treatment for high cholesterol | FIBROGEN INC | 2015-03-18 | — | — | CN | disclosed |
| US-20140309256-A1 | Therapeutic Method | FIBROGEN, INC | 2014-10-16 | — | — | US | disclosed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013070908-A1 | THERAPEUTIC METHOD | FIBROGEN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20110275697-A1 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009102469-A2 | REGULATION OF CYCLIN D | DANA FARBER CANCER INSTITUTE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885FTO 4088/4885EGLN2 215/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | EGLN1 1148/4885FTO 4102/4885EGLN2 866/4885 |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885FTO 926/4885EGLN2 2/4885 |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885EGLN2 284/4885 |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885FTO 926/4885EGLN2 2/4885 |
| US-20110275697-A1 | REGULATION OF CYCLIN D | EGLN2, EGLN1, EGLN3 | EGLN1 2/4885FTO 4043/4885EGLN2 1/4885 |
| US-20140309256-A1 | Therapeutic Method | HIF1AN, EGLN3, EGLN2 | EGLN1 6/4885FTO 1807/4885EGLN2 3/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | EGLN1 1790/4885FTO 3686/4885EGLN2 284/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | EGLN1 501/4885FTO 3763/4885EGLN2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.